AXSM Has Had An Awesome Run. What Awaits These 13 Biotech Stocks In Q2, 2019?

Shares of Axsome Therapeutics Inc. (AXSM) rose more than 6% on Monday, following positive results from its phase II trial of AXS-05 for smoking cessation treatment. Let's take a look at some more biotech companies awaiting phase II or phase III clinical trial results this quarter.

from RTT - Biotech http://bit.ly/2XjPq9h
via IFTTT